Business Context and Reporting Period
Company: Bruker Corporation (BRKR)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Bruker develops, manufactures, and distributes high-performance scientific instruments and analytical/diagnostic solutions. The company operates through four segments: BSI BioSpin, BSI CALID, BSI NANO, and Bruker Energy & Supercon Technologies (BEST).
Key Financial Metrics
| Metric (in millions) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Revenue | $797.4 | $800.7 | $1,598.8 | $1,522.4 |
| Gross Profit | $357.9 | $384.6 | $749.1 | $737.4 |
| Gross Margin | 44.9% | 48.0% | 46.9% | 48.4% |
| Operating Income | $11.9 | $48.1 | $43.7 | $112.9 |
| Operating Margin | 1.5% | 6.0% | 2.7% | 7.4% |
| Net Income (Attributable to Bruker) | $7.6 | $7.6 | $25.0 | $58.5 |
| Diluted EPS | $0.05 | $0.05 | $0.16 | $0.40 |
| Cash & Equivalents | $92.0 | $183.4 | $92.0 | $183.4 |
| Total Debt | $2,435.3 | $2,094.3 | $2,435.3 | $2,094.3 |
| Free Cash Flow (YTD) | ($109.8) | ($23.1) | ($109.8) | ($23.1) |
Material Changes vs. Prior Period
- Revenue: Q2 2025 revenue was flat (-0.4%) compared to Q2 2024, while YTD revenue grew 5.0%. Growth was driven by acquisitions (ELITechGroup, NanoString) but offset by organic declines in biopharma and industrial markets.
- Profitability: Operating income dropped significantly by 75.3% in Q2 and 61.3% YTD. Margins compressed due to higher costs of goods sold (tariffs, FX headwinds) and increased operating expenses from recent acquisitions.
- Segment Performance:
- BSI BioSpin: Revenue declined 10.2% in Q2 due to weaker demand.
- BSI CALID: Revenue increased 7.6% in Q2, driven by the ELITechGroup acquisition.
- BSI NANO: Revenue was flat in Q2; YTD growth driven by NanoString.
- BEST: Revenue declined 4.1% in Q2 due to softness in the clinical MRI market.
- Cash Flow: Operating cash flow turned negative ($62.5M used YTD) compared to positive $22.9M in the prior year, primarily due to changes in operating assets/liabilities and higher tax payments.
- Acquisitions: Completed the acquisition of Recipe Chemicals + Instruments GmbH in Q2 2025 for approximately $105 million total consideration.
Guidance, Outlook, and Risks
- Cost Savings Initiative: In August 2025, management announced an expanded cost savings initiative expected to reduce annual costs by $100 million to $120 million in 2026. This includes restructuring across supply chain, manufacturing, commercial, and R&D.
- Restructuring: A corporate-wide restructuring program was initiated in Q2 2025. Additional charges are anticipated in Q3 and Q4 2025, with activities expected to complete by 2026.
- Tariff Risks: New U.S. tariffs (10% baseline, up to 50% on steel/aluminum/copper) announced in Q2 2025 have impacted profitability. The company is assessing the impact of potential reciprocal tariffs.
- Legal Settlement: Settled patent litigation with 10x Genomics regarding NanoString products for $68.0 million, payable in installments starting Q3 2025, plus ongoing royalties.
- Tax Changes: The company is assessing the impact of the U.S. "One Big Beautiful Bill Act" (OBBBA) and German corporate tax rate reductions, with impacts expected to be recorded in Q3 2025.
Investor Verification Checklist
- Organic Growth: Verify the extent of organic revenue decline (-7.0% in Q2, -2.3% YTD) versus acquisition-driven growth.
- Restructuring Costs: Monitor upcoming quarters for the anticipated additional restructuring charges mentioned in the cost savings initiative.
- Tariff Impact: Assess the ability to pass on increased costs from new U.S. tariffs to customers.
- 10x Genomics Settlement: Track the cash outflow schedule for the $68 million settlement and the impact of royalty payments on future margins.
- Debt Levels: Review the increase in total debt to $2.4 billion and the utilization of the $900 million revolving credit facility.
- Free Cash Flow: Analyze the significant deterioration in free cash flow to negative $109.8 million YTD.